Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Immunovant (IMVT) and Henry Schein (HSIC)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Halozyme (HALO – Research Report), Immunovant (IMVT – Research Report) and Henry Schein (HSIC – Research Report).

Halozyme (HALO)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Halozyme yesterday and set a price target of $52.00. The company’s shares closed last Wednesday at $36.38.

According to TipRanks.com, Bansal is a 4-star analyst with an average return of 7.6% and a 60.3% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Halozyme has an analyst consensus of Moderate Buy, with a price target consensus of $50.57, representing a 30.0% upside. In a report issued on December 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $61.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Immunovant (IMVT)

In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on Immunovant, with a price target of $48.00. The company’s shares closed last Wednesday at $36.18.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.3% and a 45.7% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Apellis Pharmaceuticals, and Monte Rosa Therapeutics.

Currently, the analyst consensus on Immunovant is a Strong Buy with an average price target of $48.14, which is a 30.8% upside from current levels. In a report issued on December 11, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $50.00 price target.

Henry Schein (HSIC)

Bank of America Securities analyst Allen Lutz maintained a Sell rating on Henry Schein yesterday and set a price target of $65.00. The company’s shares closed last Wednesday at $73.40.

According to TipRanks.com, Lutz is a 1-star analyst with an average return of -4.0% and a 45.3% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Walgreens Boots Alliance, Patterson Companies, and Hims & Hers Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Henry Schein with a $75.38 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on HALO:

• Halozyme’s Vyvgart SC receives European Commission approval
• Halozyme price target lowered to $46 from $48 at Piper Sandler
• HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
• Halozyme raises FY23 adjusted EPS view to $2.70-$2.80 from $2.65-$2.75
• Halozyme reports Q3 adjusted EPS 75c, consensus 73c